Medigene AG (MDG1.DE)
EUR 1.08
(-1.64%)
EUR 1.08
(-1.64%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 10.65 Million EUR | -27.31% |
| 2022 | 14.65 Million EUR | -0.02% |
| 2021 | 14.65 Million EUR | -32.15% |
| 2020 | 21.59 Million EUR | -21.16% |
| 2019 | 27.39 Million EUR | 23.58% |
| 2018 | 22.16 Million EUR | -13.99% |
| 2017 | 25.77 Million EUR | -22.2% |
| 2016 | 33.12 Million EUR | 40.69% |
| 2015 | 23.54 Million EUR | 5.99% |
| 2014 | 22.21 Million EUR | 35.61% |
| 2013 | 16.37 Million EUR | -3.88% |
| 2012 | 17.04 Million EUR | 217.91% |
| 2011 | 5.36 Million EUR | -69.2% |
| 2010 | 17.4 Million EUR | 25.65% |
| 2009 | 13.85 Million EUR | -12.56% |
| 2008 | 15.84 Million EUR | 33.83% |
| 2007 | 11.83 Million EUR | -24.24% |
| 2006 | 15.62 Million EUR | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 9.15 Million EUR | 143.43% |
| 2024 Q1 | -21.06 Million EUR | -297.8% |
| 2023 Q2 | 11.98 Million EUR | 0.0% |
| 2023 Q4 | 10.65 Million EUR | 0.0% |
| 2023 Q3 | 10.65 Million EUR | -11.17% |
| 2023 FY | 10.65 Million EUR | -27.31% |
| 2023 Q1 | - EUR | -100.0% |
| 2022 Q1 | - EUR | -100.0% |
| 2022 Q4 | 14.65 Million EUR | 0.0% |
| 2022 Q2 | 17.35 Million EUR | 0.0% |
| 2022 FY | 14.65 Million EUR | -0.02% |
| 2022 Q3 | 14.65 Million EUR | -15.59% |
| 2021 Q4 | 14.65 Million EUR | 0.0% |
| 2021 Q3 | 14.65 Million EUR | -15.87% |
| 2021 Q1 | - EUR | -100.0% |
| 2021 Q2 | 17.41 Million EUR | 0.0% |
| 2021 FY | 14.65 Million EUR | -32.15% |
| 2020 Q1 | - EUR | -100.0% |
| 2020 Q4 | 21.59 Million EUR | -0.0% |
| 2020 Q2 | 23.76 Million EUR | 0.0% |
| 2020 FY | 21.59 Million EUR | -21.16% |
| 2020 Q3 | 21.59 Million EUR | -9.1% |
| 2019 Q2 | 30.37 Million EUR | 16.56% |
| 2019 FY | 27.39 Million EUR | 23.58% |
| 2019 Q4 | 27.39 Million EUR | -13.35% |
| 2019 Q3 | 31.61 Million EUR | 4.06% |
| 2019 Q1 | 26.06 Million EUR | 17.59% |
| 2018 FY | 22.16 Million EUR | -13.99% |
| 2018 Q4 | 22.16 Million EUR | -23.69% |
| 2018 Q1 | 25.05 Million EUR | -2.79% |
| 2018 Q2 | 29.24 Million EUR | 16.75% |
| 2018 Q3 | 29.04 Million EUR | -0.69% |
| 2017 Q3 | 25.81 Million EUR | -12.39% |
| 2017 Q1 | 30.86 Million EUR | -6.82% |
| 2017 FY | 25.77 Million EUR | -22.2% |
| 2017 Q4 | 25.77 Million EUR | -0.17% |
| 2017 Q2 | 29.46 Million EUR | -4.53% |
| 2016 Q4 | 33.12 Million EUR | 0.01% |
| 2016 FY | 33.12 Million EUR | 40.69% |
| 2016 Q3 | 33.12 Million EUR | 83.75% |
| 2016 Q2 | 18.02 Million EUR | -18.0% |
| 2016 Q1 | 21.98 Million EUR | -6.63% |
| 2015 Q1 | 23.87 Million EUR | 7.47% |
| 2015 Q2 | 21.36 Million EUR | -10.51% |
| 2015 FY | 23.54 Million EUR | 5.99% |
| 2015 Q4 | 23.54 Million EUR | -1.74% |
| 2015 Q3 | 23.96 Million EUR | 12.16% |
| 2014 Q4 | 22.21 Million EUR | 12.32% |
| 2014 Q2 | 19.79 Million EUR | -4.63% |
| 2014 FY | 22.21 Million EUR | 35.61% |
| 2014 Q1 | 20.75 Million EUR | 26.7% |
| 2014 Q3 | 19.77 Million EUR | -0.09% |
| 2013 Q1 | 17.26 Million EUR | 1.32% |
| 2013 FY | 16.37 Million EUR | -3.88% |
| 2013 Q3 | 15.2 Million EUR | -5.93% |
| 2013 Q2 | 16.16 Million EUR | -6.37% |
| 2013 Q4 | 16.37 Million EUR | 7.7% |
| 2012 Q3 | 16.74 Million EUR | 0.67% |
| 2012 Q1 | 3.94 Million EUR | -26.4% |
| 2012 FY | 17.04 Million EUR | 217.91% |
| 2012 Q4 | 17.04 Million EUR | 1.76% |
| 2012 Q2 | 16.63 Million EUR | 321.67% |
| 2011 FY | 5.36 Million EUR | -69.2% |
| 2011 Q1 | 9.08 Million EUR | -47.81% |
| 2011 Q2 | 5.73 Million EUR | -36.84% |
| 2011 Q3 | 5.45 Million EUR | -4.95% |
| 2011 Q4 | 5.36 Million EUR | -1.69% |
| 2010 FY | 17.4 Million EUR | 25.65% |
| 2010 Q4 | 17.4 Million EUR | 1.71% |
| 2010 Q3 | 17.11 Million EUR | 62.94% |
| 2010 Q2 | 10.5 Million EUR | -7.63% |
| 2010 Q1 | 11.36 Million EUR | -17.91% |
| 2009 FY | 13.85 Million EUR | -12.56% |
| 2009 Q4 | 13.85 Million EUR | 0.0% |
| 2008 FY | 15.84 Million EUR | 33.83% |
| 2007 FY | 11.83 Million EUR | -24.24% |
| 2006 FY | 15.62 Million EUR | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| BioNTech SE | 2.76 Billion EUR | 99.614% |
| CureVac N.V. | 271.53 Million EUR | 96.078% |
| Biotest Aktiengesellschaft | 945.4 Million EUR | 98.873% |
| Biotest Aktiengesellschaft | 945.4 Million EUR | 98.873% |
| BRAIN Biotech AG | 47.92 Million EUR | 77.777% |
| Formycon AG | 387.61 Million EUR | 97.252% |
| Heidelberg Pharma AG | 21.01 Million EUR | 49.318% |